We are thrilled to announce that Symcel has been awarded a grant to further develop fast diagnostics for prosthesis and joint infections. This exciting development represents a major step forward in our ongoing efforts to improve patient outcomes...
This week we are happy to welcome a brand new addition to the Symcel family, Kasper Kragh.
- This shift in metabolism has strong implications for tolerance to antibiotics
Today our Principal Scientist, Dr. Marta Veses Garcia will present at the United States Pharmacopeia event.
- The move brings Symcel closer to one of the world's biggest life science hubs
– The funding will also accelerate the commercialization of Symcel’s R&D product offering (STOCKHOLM) Symcel — a company providing real-time metabolic measurements of living organisms with their analytical instrument the calScreener™ ̶ today...
– New antibiotic potentiating activity has been discovered for treatment of Cystic Fibrosis associate infections. (STOCKHOLM) Symcel— a company providing real-time metabolic measurements for bacteria and cell culture with their product the...
– A new screening method will help to discover drugs that force the body to burn fat reserves. (STOCKHOLM) Symcel— a company providing real-time metabolic measurements for cell culture with their product the calScreener™ ̶ was recently involved in a...
– This metabolism has been directly measured for the first time using microcalorimetry (STOCKHOLM) Symcel— a company providing real-time metabolic measurements for cell culture with their product the calScreener™ ̶ was recently involved in a...
– Metabolic readouts highlighted which treatment parameters were most effective. (STOCKHOLM) Symcel— a company providing real-time metabolic measurements for cell culture with their product the calScreener™ ̶ was recently involved in a publication...